← Back to search
NOMOCAN PHARMACEUTICALS LLC
NEW YORK, NY, 10065
UnclaimedClaim this profile (free)
Prime contracting experience
2 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | PHASE I - DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENTION OF PEDIATRIC CANCERS AND/OR RARE CANCERS SBIR CONTRACTRIPTION. | — | $499,166 | Sep 1, 2026 | Sep 15, 2025 – Sep 14, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | PC HAS ONE OF THE LOWEST 5-YEAR SURVIVAL RATES AMONG ALL CANCER TYPES, REMAINING BELOW 10% FOR THE PAST 40 YEARS, INDICATING A NEED FOR EFFECTIVE PC THERAPIES. STUDIES HAVE SHOWN THAT NMC-521 BINDS SELECTIVELY TO SEVERAL PC CELL LINES WITH MARKED ANT | — | $354,959 | Mar 21, 2024 | Feb 27, 2023 – Nov 26, 2024 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.